Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 3/20 | 0.66 |
| ▸ | CNR1 | P21554 | 2/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.64 |
| ▸ | MEN1 | O00255 | 1/20 | 0.64 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.60 |
| ▸ | LMNA | P02545 | 2/20 | 0.60 |
| ▸ | TSHR | P16473 | 2/20 | 0.60 |
| ▸ | USP2 | O75604 | 1/20 | 0.60 |
| ▸ | TP53 | P04637 | 1/20 | 0.60 |
| ▸ | GAA | P10253 | 1/20 | 0.60 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.60 |
| ▸ | PKM | P14618 | 1/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.59 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.55 |
| ▸ | NPC1 | O15118 | 1/20 | 0.55 |
| ▸ | RAB9A | P51151 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5623047 | 0.86 | MAPK1 (0.77) | CNR2CNR1KMT2AMAPK1ALDH1A1 | |
| SCHEMBL11185044 | 0.86 | MAPK1 (0.77) | CNR2CNR1KMT2AMAPK1ALDH1A1 | |
| SCHEMBL4716079 | 0.84 | TDP1 (0.76) | CNR1KMT2AMEN1ALDH1A1LMNA | |
| SCHEMBL7664954 | 0.84 | PKM (0.61) | CNR2CNR1KMT2AALDH1A1LMNA | |
| SCHEMBL7659574 | 0.84 | PKM (0.61) | CNR2CNR1KMT2AALDH1A1LMNA | |
| SCHEMBL4252422 | 0.83 | SMN1; SMN2 (0.77) | CNR2CNR1KMT2AALDH1A1LMNA | |
| SCHEMBL4717858 | 0.83 | LMNA (0.70) | KMT2AMEN1MAPK1ALDH1A1LMNA | |
| SCHEMBL14530332 | 0.83 | PKM (0.60) | CNR2CNR1KMT2AALDH1A1LMNA | |
| SCHEMBL7688673 | 0.82 | PKM (0.62) | CNR2CNR1KMT2AALDH1A1LMNA | |
| SCHEMBL7663722 | 0.82 | ALDH1A1 (0.64) | KMT2AMEN1ALDH1A1LMNAPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7544676-B2 | Sulfamoyl benzamides and methods of their use | ADOLOR CORPORATION (US) | 2009-06-09 | — | — | US | disclosed |
| US-7544676-B2 | Sulfamoyl benzamides and methods of their use | ADOLOR CORPORATION (US) | 2009-06-09 | — | — | US | disclosed |
| US-7544676-B2 | Sulfamoyl benzamides and methods of their use | ADOLOR CORPORATION (US) | 2009-06-09 | — | — | US | disclosed |
| US-20080058302-A1 | Sulfamoyl Benzamides and Methods of Their Use | CALIXA THERAPEUTICS, INC. | 2008-03-06 | — | — | US | disclosed |
| US-20080058302-A1 | Sulfamoyl Benzamides and Methods of Their Use | CALIXA THERAPEUTICS, INC. | 2008-03-06 | — | — | US | disclosed |
| US-20080058302-A1 | Sulfamoyl Benzamides and Methods of Their Use | CALIXA THERAPEUTICS, INC. | 2008-03-06 | — | — | US | disclosed |
| WO-2007058960-A1 | SULFAMOYL BENZAMIDES AS CANNABINOID RECEPTOR MODULATORS | ADOLOR CORPORATION (US) | 2007-05-24 | — | — | WO | disclosed |
| WO-2007058960-A1 | SULFAMOYL BENZAMIDES AS CANNABINOID RECEPTOR MODULATORS | ADOLOR CORPORATION (US) | 2007-05-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080058302-A1 | Sulfamoyl Benzamides and Methods of Their Use | CNR2, TRPV1, CNR1 | CNR2 1/4885CNR1 3/4885KMT2A 683/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.